TP53 Mutation and p53 Overexpression for Prediction of Response to Neoadjuvant Treatment in Breast Cancer Patients

The value of p53 to predict the cytotoxic effect of two commonly used chemotherapy regimens was assessed in patients with advanced breast cancer. Response to a DNA-damaging combination therapy [fluorouracil, epirubicin, cyclophosphamide (FEC)] considered to induce p53-dependent apoptosis was compare...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2000-01, Vol.6 (1), p.50-56
Hauptverfasser:	KANDIOLER-ECKERSBERGER, D, LUDWIG, C, JAKESZ, R, RUDAS, M, KAPPEL, S, JANSCHEK, E, WENZEL, C, SCHLAGBAUER-WADL, H, MITTLBÖCK, M, GNANT, M, STEGER, G
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic agents Antineoplastic Agents, Phytogenic - adverse effects Antineoplastic Agents, Phytogenic - therapeutic use Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Apoptosis Biological and medical sciences Breast Neoplasms - drug therapy Breast Neoplasms - genetics Breast Neoplasms - pathology Breast Neoplasms - surgery Chemotherapy Codon Cyclophosphamide - administration & dosage Epirubicin - administration & dosage Exons Female Fluorouracil - administration & dosage Genes, p53 Humans Immunohistochemistry Introns Medical sciences Mutation Neoadjuvant Therapy Neoplasm Staging Paclitaxel - adverse effects Paclitaxel - therapeutic use Pharmacology. Drug treatments Tumor Suppressor Protein p53 - analysis Tumor Suppressor Protein p53 - genetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!